Vibrant Gastro is a technology company.
Vibrant Gastro has raised $8.0M across 1 funding round.
Vibrant Gastro has raised $8.0M in total across 1 funding round.
Vibrant Gastro has raised $8.0M in total across 1 funding round.
Vibrant Gastro's investors include Sequoia Capital Israel.
Vibrant Gastro is a pioneering medical technology company that develops a first-of-its-kind, FDA-cleared, drug-free treatment for chronic idiopathic constipation (CIC). Its flagship product, the Vibrant System™, is a vibrating capsule that mechanically stimulates the colon using micro-vibrations to enhance natural colonic motility without chemicals. This innovation targets millions of patients suffering from chronic constipation, offering a safer, non-pharmaceutical alternative that improves bowel movements and quality of life. The company’s mission is to synchronize and activate the gut-brain connection to provide predictable symptom relief and enable patients to live fuller lives[1][2][5].
Founded around 2010, Vibrant Gastro was co-founded by Lior Ben Tsur, who served as CEO and clinical lead until 2023. Lior brought 35 years of experience in Med-Tech and Hi-Tech startups, contributing to the invention and design of the Vibrant holistic system. The idea emerged from the need for a drug-free, effective treatment for chronic constipation, a condition with limited safe options. Early traction included clinical validation and FDA clearance, positioning Vibrant as a leader in bioelectronic medicine for gastrointestinal disorders. The leadership team also includes Asaf Bar, with over 20 years of experience in business development and medical device industries, and Dr. Brennan Spiegel, a recognized expert in digital health and gastrointestinal research[1][3].
Vibrant Gastro rides the growing trend of bioelectronic medicine, which uses device-based therapies to modulate physiological functions without drugs. This approach aligns with increasing demand for safer, non-pharmaceutical treatments amid concerns about drug side effects and opioid overuse. The timing is favorable due to rising chronic gastrointestinal disorders and advances in miniaturized electronics and digital health. Vibrant’s innovation influences the broader ecosystem by demonstrating how technology can address complex chronic conditions through gut-brain axis modulation, potentially inspiring further development in bioelectronic therapeutics[1][3][4].
Looking ahead, Vibrant Gastro is positioned to expand access through federal contracts (e.g., Veterans and Tricare members) and broaden its market reach. Future trends shaping its journey include advances in personalized medicine, integration with digital health platforms, and growing acceptance of bioelectronic therapies. As the company scales, it may extend its technology to other gastrointestinal or neurological disorders, deepening its influence in the intersection of technology and medicine. Vibrant Gastro exemplifies how innovative, drug-free solutions can transform chronic disease management, offering hope and improved quality of life to millions[5][3].
Vibrant Gastro has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series E in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $8.0M Series E | Sequoia Capital Israel |